List of Excipients in Branded Drug ZITUVIO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Zydus Pharmaceuticals (USA) Inc	ZITUVIO	sitagliptin	70710-1240	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	2035-02-25
Zydus Pharmaceuticals (USA) Inc	ZITUVIO	sitagliptin	70710-1240	CELLULOSE, MICROCRYSTALLINE	2035-02-25
Zydus Pharmaceuticals (USA) Inc	ZITUVIO	sitagliptin	70710-1240	CROSCARMELLOSE SODIUM	2035-02-25
Zydus Pharmaceuticals (USA) Inc	ZITUVIO	sitagliptin	70710-1240	MAGNESIUM STEARATE	2035-02-25

ZITUVIO Excipient Strategy and Commercial Opportunities for Sitagliptin Tablets

Last updated: August 2, 2026

ZITUVIO is Zydus Lifesciences' sitagliptin phosphate immediate-release tablet, marketed in 25 mg, 50 mg and 100 mg strengths for type 2 diabetes. Its commercial value comes from access to the former Januvia market, while its excipient strategy is conventional, scalable and designed to support a low-cost, bioequivalent oral solid dosage product. The strongest opportunities are supply-cost optimization, differentiated packaging, combination products and expansion in price-sensitive markets rather than novel excipient-based lifecycle extension.

What is ZITUVIO and how is it regulated?

ZITUVIO contains sitagliptin phosphate monohydrate, a dipeptidyl peptidase-4 inhibitor. The product is an immediate-release, film-coated tablet indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not indicated for treatment of type 1 diabetes or diabetic ketoacidosis (U.S. Food and Drug Administration [FDA], 2022).

Product attribute	ZITUVIO position
Active ingredient	Sitagliptin phosphate monohydrate
Therapeutic class	DPP-4 inhibitor
Dosage form	Immediate-release film-coated tablet
Strengths	25 mg, 50 mg, 100 mg
Primary U.S. sponsor	Zydus Lifesciences
Administration	Once daily, with or without food
Renal dosing	Required for moderate and severe renal impairment
Reference product	JANUVIA, Merck
FDA pathway	FDA-approved sitagliptin tablet product
Primary commercial market	Type 2 diabetes treatment
Core formulation opportunity	Cost, robustness, supply reliability and market access

Sitagliptin is eliminated primarily through the kidneys. The 25 mg and 50 mg strengths support renal dose adjustment, while the 100 mg strength is the standard adult dose for patients with normal renal function or mild renal impairment (FDA, 2022).

What excipients are used in ZITUVIO tablets?

The ZITUVIO label identifies a conventional tablet platform. Public labeling identifies inactive ingredients that include microcrystalline cellulose, dibasic calcium phosphate anhydrous, croscarmellose sodium, magnesium stearate, sodium stearyl fumarate and sodium lauryl sulfate. The film coat includes standard coating materials such as hypromellose, polyethylene glycol, talc, titanium dioxide and colorants, including iron oxide where applicable (FDA, 2022).

Excipient category	Likely function in ZITUVIO
Microcrystalline cellulose	Diluent, compactibility and tablet structure
Dibasic calcium phosphate anhydrous	Mineral diluent, density and compression support
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant
Sodium stearyl fumarate	Secondary or complementary lubricant
Sodium lauryl sulfate	Wetting and dispersion aid
Hypromellose	Film-forming polymer
Polyethylene glycol	Plasticizer in the film coat
Talc	Anti-tacking and coating-processing aid
Titanium dioxide	Opacifier and whitening agent
Iron oxide	Tablet color differentiation

The formulation is consistent with a high-volume, immediate-release tablet strategy. It does not depend on a modified-release polymer, enteric coating, lipid system, complexation technology or specialized drug-delivery platform.

Why is the ZITUVIO excipient strategy commercially relevant?

The formulation supports four commercial objectives.

First, the use of established direct-compression excipients can reduce process complexity. Microcrystalline cellulose and dibasic calcium phosphate provide complementary compression properties. Microcrystalline cellulose supports compactibility, while dibasic calcium phosphate contributes density and relatively low moisture sensitivity.

Second, dual-lubricant use can improve manufacturing robustness. Magnesium stearate is widely used but can cause over-lubrication and dissolution changes when mixing is excessive. Sodium stearyl fumarate can provide an alternative lubrication profile. The commercial value depends on the validated manufacturing process, not merely on the presence of either excipient.

Third, croscarmellose sodium and sodium lauryl sulfate help manage tablet wetting and disintegration. This is important for a low-dose active pharmaceutical ingredient distributed within a larger tablet mass. The product must deliver consistent dissolution across strengths while remaining mechanically robust during packaging and transport.

Fourth, film coating creates an economical platform for strength identification and patient acceptability. Color-coded 25 mg, 50 mg and 100 mg tablets reduce dispensing errors and simplify visual differentiation in pharmacies and institutional settings.

What formulation patents protect ZITUVIO?

The principal commercial protection for sitagliptin historically arose from Merck's active-ingredient, salt, formulation and regulatory exclusivity positions surrounding JANUVIA. ZITUVIO's market entry reflects the expiration, licensing or resolution of relevant barriers to sitagliptin tablet commercialization rather than a publicly marketed novel excipient platform.

Public product labeling does not establish that ZITUVIO has a proprietary excipient composition with independent commercial exclusivity. The identified excipients are widely used pharmaceutical materials. Their use alone would generally provide limited freedom-to-operate value because the ingredients and functions are established in the prior art.

Potentially protectable areas include:

• Specific excipient ratios that improve dissolution or content uniformity.
• Low-moisture manufacturing processes.
• Lubrication sequences that reduce dissolution variability.
• Film-coating compositions that improve stability or color uniformity.
• Granulation or blending processes for low-dose sitagliptin distribution.
• Packaging systems that control humidity and protect tablet integrity.
• Fixed-dose combinations containing sitagliptin and another antidiabetic agent.

A commercial patent review should distinguish patents covering sitagliptin itself from patents covering sitagliptin phosphate, polymorphs, combinations, manufacturing processes and clinical methods of use. The public ZITUVIO label does not by itself identify a separate, enforceable Zydus excipient patent estate.

When does sitagliptin lose exclusivity?

JANUVIA's loss of exclusivity occurred after the expiration or resolution of key U.S. sitagliptin patent rights. Merck's U.S. patent and regulatory protection historically delayed broad generic entry, with market entry timing affected by Paragraph IV certifications, patent litigation and settlement arrangements.

Exclusivity factor	Commercial impact
Active-ingredient and salt patents	Delayed competing sitagliptin products
Formulation or crystalline-form claims	Potentially extended product protection
Pediatric exclusivity	Could add six months to qualifying patents
Paragraph IV litigation	Can trigger a 30-month stay under the Hatch-Waxman framework
Settlement agreements	May establish authorized or licensed entry dates
Orange Book listings	Define patents that generic applicants must address
FDA approval status	Determines whether commercial launch can occur

ZITUVIO's entry position is therefore more important than the nominal expiration date of any single patent. The relevant business question is whether a competing company can obtain approval and launch without infringing enforceable claims, not simply whether the original compound patent has expired.

What is the Orange Book status of ZITUVIO?

The Orange Book principally identifies approved drug products and patent information submitted by the relevant NDA holder. For ZITUVIO, the practical Orange Book analysis should separate three categories:

1. Patents listed against the reference product JANUVIA.
2. Any patents listed against ZITUVIO's own approved application.
3. Regulatory exclusivity or patent certifications associated with competing sitagliptin products.

ZITUVIO should not automatically be treated as having the same Orange Book patent estate as JANUVIA. A generic or follow-on applicant must review the specific listed patents for the reference product and the certification requirements associated with its application. A product-specific Orange Book listing can also differ from a compound-level patent position.

Are Paragraph IV challenges affecting ZITUVIO?

Paragraph IV challenges have been central to generic sitagliptin entry. Under the Hatch-Waxman Act, an applicant can certify that a listed patent is invalid, unenforceable or not infringed. The reference-product sponsor may then bring patent litigation, potentially triggering a statutory approval stay.

The commercial consequences include:

• Delayed launch despite technical approval.
• Litigation costs and settlement payments.
• Restricted launch dates.
• Authorized-generic arrangements.
• At-risk launch exposure if the applicant launches before final patent resolution.
• Reduced expected price if several applicants enter simultaneously.

ZITUVIO's competitive position improves when it has a negotiated or legally cleared launch path. It weakens if multiple applicants receive approval with similar entry rights, because the resulting price competition can rapidly reduce gross margins.

How strong is the ZITUVIO patent estate?

ZITUVIO's direct excipient patent position appears limited based on publicly available product information. Its commercial strength is more likely to depend on regulatory approval, manufacturing scale, distribution and the ability to compete after originator exclusivity.

Patent-estate dimension	Assessment
Novel excipient platform	Limited public evidence
Immediate-release tablet composition	Likely low differentiation
Manufacturing know-how	Potentially meaningful but confidential
Combination-product protection	Higher potential
Packaging and stability claims	Moderate opportunity
Method-of-use claims	Primarily tied to sitagliptin clinical use
Brand and distribution position	Commercially relevant
Barrier to generic substitution	Low once multiple products are approved

Manufacturing know-how can still have economic value even without strong composition patents. Blend uniformity, tablet hardness, dissolution control, coating yield and stability performance can reduce batch failures and support lower cost of goods.

What commercial opportunities exist for ZITUVIO excipients?

Cost reduction and supply-chain resilience

The largest near-term opportunity is dual sourcing of standard excipients. Microcrystalline cellulose, calcium phosphate, croscarmellose sodium and coating materials are available from multiple global suppliers. Zydus can reduce supply risk by qualifying alternative grades with comparable particle-size distribution, moisture content, bulk density and functionality.

Supplier changes require attention to:

• Compaction behavior.
• Blend segregation.
• Tablet friability.
• Disintegration time.
• Dissolution profiles.
• Lubrication sensitivity.
• Film-coating uniformity.
• Long-term stability.

Strength-specific optimization

The 25 mg, 50 mg and 100 mg tablets may use proportional or partially proportional excipient systems. A single manufacturing platform is commercially attractive, but low-dose products create greater content-uniformity risk. Strength-specific adjustment of diluent and disintegrant levels may improve robustness without changing the product's therapeutic profile.

Fixed-dose combinations

Sitagliptin has established combination potential with metformin, and DPP-4 inhibitors are used alongside other glucose-lowering agents. Combination products can reduce pill burden and create differentiated regulatory and commercial positions.

Potential products include:

• Sitagliptin and metformin immediate-release tablets.
• Sitagliptin and metformin extended-release products.
• Sitagliptin combinations with sodium-glucose cotransporter-2 inhibitors.
• Co-packaged regimens for patients requiring sequential intensification.

Combination products create higher formulation complexity because the manufacturer must control interactions between active ingredients, dissolution behavior and dose flexibility.

Emerging-market formulation opportunities

In India, Latin America, Southeast Asia, the Middle East and Africa, excipient strategy can support lower-cost products and climate-resilient distribution. Relevant design priorities include:

• Reduced moisture uptake.
• High-temperature stability.
• Strong tablets for transport.
• Affordable blister or bottle packaging.
• Simple once-daily dosing.
• Local excipient sourcing.
• Flexible manufacturing-site qualification.

Blister packaging may offer better unit-dose protection, while bottles can reduce packaging cost. The choice depends on humidity exposure, reimbursement, dispensing practice and channel economics.

How does ZITUVIO compare with JANUVIA and other DPP-4 inhibitors?

Product	Active ingredient	Dosage form	Commercial differentiation
ZITUVIO	Sitagliptin phosphate	Immediate-release tablet	Lower-cost sitagliptin access
JANUVIA	Sitagliptin phosphate	Immediate-release tablet	Originator brand, established prescribing base
JANUMET	Sitagliptin plus metformin	Immediate or extended-release tablet	Fixed-dose combination
TRADJENTA	Linagliptin	Immediate-release tablet	No renal dose adjustment in labeling
ONGLYZA	Saxagliptin	Immediate-release tablet	DPP-4 alternative with distinct dosing considerations
NESINA	Alogliptin	Immediate-release tablet	Alternative DPP-4 inhibitor

ZITUVIO's strongest advantage is molecule familiarity and generic pricing. Linagliptin may retain a clinical positioning advantage for patients with renal impairment because it does not require the same degree of renal dose adjustment. Sitagliptin's countervailing strengths are long clinical use, extensive physician familiarity and a large installed patient base.

What generic entry risks exist for ZITUVIO?

ZITUVIO faces standard post-exclusivity generic risks.

The first is rapid price erosion. Once several sitagliptin manufacturers enter, pharmacy benefit managers and wholesalers can treat the product as a commodity.

The second is authorized-generic competition. An originator-sponsored or licensed generic can enter with strong manufacturing and distribution support, limiting the margin available to independent suppliers.

The third is combination-product substitution. Patients may move from sitagliptin monotherapy to lower-cost metformin combinations or to newer classes such as SGLT2 inhibitors and GLP-1 receptor agonists.

The fourth is reimbursement pressure. DPP-4 inhibitors can lose formulary position when payers prioritize lower-cost generics or products with cardiovascular, renal or weight-loss advantages.

The fifth is excipient and manufacturing disruption. A low-cost product remains commercially vulnerable if a supplier change causes dissolution failures, recall risk or regulatory observations.

What is the revenue exposure associated with sitagliptin?

Merck's JANUVIA franchise generated multibillion-dollar global revenue before and during the transition to generic competition. Merck reported JANUVIA and JANUMET sales as a major component of its diabetes portfolio, with revenue pressure expected as patent protection weakened and generic sitagliptin products entered key markets (Merck & Co., 2024).

ZITUVIO cannot capture the entire originator market. Its realistic opportunity depends on:

• The number of approved competitors.
• Entry timing relative to other applicants.
• Net price after rebates.
• Payer substitution rules.
• Zydus' manufacturing cost.
• Distribution coverage.
• Availability of combination products.
• Geographic launch sequence.

The most defensible commercial strategy is a portfolio approach: low-cost monotherapy, sitagliptin-metformin combinations, regional launches and manufacturing redundancy.

What licensing deals and settlement agreements matter?

Sitagliptin commercialization has involved originator patent settlements and market-entry arrangements in several jurisdictions. The economic terms and permitted launch dates of those agreements can materially affect ZITUVIO's value, but public product labeling does not provide a complete record of private licensing terms.

For diligence purposes, the relevant agreement terms are:

• Authorized launch date.
• Geographic scope.
• Royalty obligations.
• Supply requirements.
• Restrictions on formulation or combination products.
• Rights to sublicense.
• Authorized-generic provisions.
• Litigation dismissal terms.
• Treatment of future patents.

A settlement that permits early entry can have greater value than a formulation patent with a later expiration date if competing products are excluded during the permitted launch window.

Key Takeaways

• ZITUVIO is an immediate-release sitagliptin phosphate tablet in 25 mg, 50 mg and 100 mg strengths.
• Its excipient system is conventional and optimized for manufacturability, dissolution and cost rather than novel delivery.
• Microcrystalline cellulose, dibasic calcium phosphate, croscarmellose sodium, standard lubricants and a hypromellose film coat support a scalable tablet platform.
• Public product information does not establish a strong proprietary excipient patent estate for ZITUVIO.
• The main commercial opportunity is post-JANUVIA generic substitution, supported by low manufacturing cost and broad distribution.
• Fixed-dose sitagliptin combinations, especially with metformin, offer greater differentiation than monotherapy.
• The largest risks are rapid price erosion, authorized-generic competition, payer substitution and manufacturing or supply-chain disruption.
• Patent settlements, Orange Book certifications and launch timing are more commercially important than the use of standard excipients.

FAQs

Can ZITUVIO use a different excipient system from JANUVIA?

Yes. An approved follow-on or generic product can use different inactive ingredients if it satisfies applicable quality, bioequivalence, stability and labeling requirements. The alternative formulation must maintain suitable dissolution, content uniformity and tablet performance.

Is ZITUVIO an extended-release sitagliptin product?

No. ZITUVIO is labeled as an immediate-release film-coated tablet. Extended-release technology is associated primarily with combination products such as sitagliptin and metformin extended-release formulations.

Which excipients are most important for sitagliptin dissolution?

Croscarmellose sodium supports disintegration, while sodium lauryl sulfate can improve wetting. Tablet compression, lubricant concentration and blending time can also affect dissolution performance.

Does sitagliptin require a special excipient for renal impairment?

No. Renal impairment is managed through sitagliptin dose adjustment. The product does not require a renal-targeted delivery system or specialized excipient.

Can ZITUVIO be reformulated into a pediatric product?

A pediatric formulation could use a lower-strength tablet, orally disintegrating tablet, granule or oral liquid. Such a product would require separate development, stability work, palatability assessment and regulatory support.

References

1. Merck & Co., Inc. (2024). 2023 annual report. https://www.merck.com
2. U.S. Food and Drug Administration. (2022). ZITUVIO (sitagliptin phosphate) tablets prescribing information. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs
4. U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the Hatch-Waxman Act and Paragraph IV certifications. https://www.fda.gov/drugs
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.